Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-07 22:24 | 2026-10-05 | BCYC | BICYCLE THERAPEUTICS PLC | Perry Jennifer Scott | Officer | SELL | $3.76 | 356 | $1,339 | 89,602 |
| 2026-10-07 21:44 | 2026-10-06 | JAZZ | Jazz Pharmaceuticals plc | GALA RENEE D | Director, Officer | SELL | $236.40 | 2,000 | $472,800 | 141,394 |
| 2026-10-07 21:20 | 2026-10-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $64.06 | 2,073 | $132,791 | 105,272 |
| 2026-10-07 21:02 | 2026-10-05 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | Officer | SELL | $1.99 | 294 | $585 | 81,715 |
| 2026-10-07 20:30 | 2026-10-05 | LQDA | Liquidia Corp | Bloch Stephen M | Director | SELL | $27.13 | 235,477 | $6,387,596 | 0 |
| 2026-10-07 20:35 | 2026-10-06 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $538.67 | 9,500 | $5,117,412 | 324,443 |
| 2026-10-07 20:00 | 2026-10-05 | AMLX | Amylyx Pharmaceuticals, Inc. | MILNE GEORGE M JR | Director | SELL | $27.70 | 30,000 | $830,904 | 782,881 |
| 2026-10-07 19:45 | 2026-10-07 | EBS | Emergent BioSolutions Inc. | DeGolyer Donald W | Director | SELL | $7.09 | 17,800 | $126,202 | 111,921 |
| 2026-10-06 20:12 | 2026-10-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | SUPRAN BRYAN | Officer | SELL | $226.88 | 1,758 | $398,855 | 12,807 |
| 2026-10-06 21:24 | 2026-10-06 | CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | CTT PHARMACEUTICAL HOLDINGS, INC. | Director, Officer | BUY | $0.06 | 3,700 | $204 | 9,433,656 |
| 2026-10-06 20:43 | 2026-10-02 | OCUL | OCULAR THERAPEUTIX, INC | Heier Jeffrey S. | Officer | SELL | $7.05 | 10,869 | $76,626 | 307,457 |
| 2026-10-06 20:44 | 2026-10-02 | OCUL | OCULAR THERAPEUTIX, INC | Kaiser Peter | Officer | SELL | $7.05 | 9,990 | $70,430 | 254,388 |
| 2026-10-06 20:45 | 2026-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Lee Kevin | Director, Officer | SELL | $3.49 | 7,805 | $27,247 | 595,866 |
| 2026-10-06 20:45 | 2026-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Perry Jennifer Scott | Officer | SELL | $3.54 | 1,500 | $5,313 | 89,552 |
| 2026-10-06 20:45 | 2026-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Hannay Michael Charles Ferguson | Officer | SELL | $3.48 | 1,814 | $6,319 | 92,561 |
| 2026-10-06 20:45 | 2026-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Skynner Michael | Officer | SELL | $3.49 | 2,445 | $8,535 | 154,726 |
| 2026-10-06 20:45 | 2026-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Swanton Robert Charles | Director | SELL | $3.47 | 3,431 | $11,906 | 15,782 |
| 2026-10-06 20:49 | 2026-10-06 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Officer | OPT+S | $55.07 | 4,166 | $229,406 | 43,381 |
| 2026-10-06 20:25 | 2026-10-06 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $61.38 | 3,500 | $214,830 | 153,902 |
| 2026-10-06 20:32 | 2026-10-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $541.64 | 9,500 | $5,145,537 | 324,443 |
| 2026-10-06 20:34 | 2026-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Thompson Travis Alvin | Officer | SELL | $3.48 | 972 | $3,381 | 64,449 |
| 2026-10-06 20:35 | 2026-10-02 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | OPT+S | $304.07 | 5,000 | $1,520,346 | 31,854 |
| 2026-10-06 20:15 | 2026-10-02 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | BUY | $16.00 | 2,500 | $40,000 | 27,000 |
| 2026-10-06 17:53 | 2026-10-02 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | BUY | $8.57 | 100,000 | $857,240 | 314,000 |
| 2026-10-06 11:00 | 2026-10-01 | RDHL | RedHill Biopharma Ltd. | Raday Gilead | Officer | OPT+S | $0.00 | 14,310,000 | $1,431 | 176,910,000 |
| 2026-10-05 21:12 | 2026-10-05 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $57.10 | 4,126 | $235,595 | 0 |
| 2026-10-05 21:11 | 2026-10-01 | INM | InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC | 10% owner | BUY | $1.33 | 42,920 | $57,079 | 935,021 |
| 2026-10-05 20:57 | 2026-10-01 | ELVN | Enliven Therapeutics, Inc. | Garland J. Scott | Director | OPT+S | $46.67 | 13,000 | $606,719 | 0 |
| 2026-10-05 20:03 | 2026-10-01 | RMTI | ROCKWELL MEDICAL, INC. | Strobeck Mark | Director, Officer | SELL | $8.42 | 1,000 | $8,420 | 61,349 |
| 2026-10-05 23:58 | 2026-10-02 | CORT | CORCEPT THERAPEUTICS INC | Vieira Roberto Wandenkolk | Officer | OPT+S | $116.10 | 8,333 | $967,448 | 3,946 |
| 2026-10-05 23:49 | 2026-10-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $116.26 | 25,000 | $2,906,603 | 9,938 |
| 2026-10-05 23:54 | 2026-10-01 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $116.07 | 10,000 | $1,160,731 | 5,683 |
| 2026-10-05 23:27 | 2026-10-01 | BLTE | BELITE BIO, INC | Scholl Hendrik Peter | Officer | SELL | $165.32 | 500 | $82,659 | 14,500 |
| 2026-10-05 22:46 | 2026-10-01 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% owner | BUY | $2.05 | 60,490 | $123,817 | 2,858,657 |
| 2026-10-05 22:05 | 2026-10-01 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Director | OPT+S | $36.10 | 17,750 | $640,860 | 14,954 |
| 2026-10-05 21:43 | 2026-10-01 | MNPR | Monopar Therapeutics | STARR CHRISTOPHER M | Director | OPT+S | $78.50 | 8,400 | $659,387 | 5,173 |
| 2026-10-05 21:36 | 2026-10-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | OPT+S | $24.47 | 27,000 | $660,795 | 115,743 |
| 2026-10-05 20:53 | 2026-10-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $549.37 | 9,500 | $5,219,015 | 324,443 |
| 2026-10-05 20:18 | 2026-10-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $230.33 | 6,000 | $1,381,980 | 345,875 |
| 2026-10-05 13:16 | 2026-10-01 | EBS | Emergent BioSolutions Inc. | Williams Paul Anthony | Officer | SELL | $6.53 | 3,000 | $19,590 | 156,098 |
| 2026-10-02 20:30 | 2026-09-30 | NAMS | NewAmsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Director, Officer | OPT+S | $25.03 | 50,246 | $1,257,657 | 69,302 |
| 2026-10-02 20:54 | 2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | Officer | SELL | $9.41 | 5,000 | $47,037 | 1,351,053 |
| 2026-10-02 20:54 | 2026-10-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | Officer | SELL | $9.41 | 15,000 | $141,120 | 1,599,208 |
| 2026-10-02 20:30 | 2026-09-29 | HEPA | Hepion Pharmaceuticals, Inc. | Fisher Danina | Director | BUY | $0.05 | 200,000 | $10,000 | 200,000 |
| 2026-10-02 20:01 | 2026-10-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $1.19 | 378 | $450 | 23,404 |
| 2026-10-02 20:10 | 2026-09-30 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | OPT+S | $141.78 | 58,629 | $8,312,296 | 59,003 |
| 2026-10-02 20:31 | 2026-10-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $576.47 | 9,500 | $5,476,462 | 324,443 |
| 2026-10-03 01:29 | 2026-09-30 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $90.47 | 25,000 | $2,261,830 | 79,762 |
| 2026-10-03 01:29 | 2026-10-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $92.01 | 15,000 | $1,380,105 | 537,540 |
| 2026-10-03 01:30 | 2026-10-01 | SYRE | Spyre Therapeutics, Inc. | King-Jones Heidy | Officer | OPT+S | $91.03 | 28,933 | $2,633,901 | 2,845 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.